MiNK Therapeutics Extends Cash Runway, Advances Clinical Milestones, and Pursues Strategic Partnerships

MiNK Therapeutics reported a $4.2 million net loss in Q2 2025 and announced a $13 million equity raise, extending its cash runway through mid-2026. The company highlighted a published complete remission case with AGENT-797 in metastatic testicular cancer, a year-over-year operating cash burn reduction of over 30%, and new external funding for upcoming clinical trials. Strategic partnerships and clinical milestones in cancer, including a complete response in metastatic testicular cancer and durable tumor shrinkage in gastric cancer, have drawn renewed interest from investors and potential partners.

MiNK Therapeutics, Inc. (NASDAQ: INKT) has reported a $4.2 million net loss for the second quarter ended June 30, 2025, while also announcing a $13 million equity raise. This funding extends the company's cash runway through mid-2026 [1]. The company's latest financial report highlights a significant reduction in operating cash burn, a year-over-year decrease of over 30%, and new external funding for upcoming clinical trials.

MiNK Therapeutics has achieved notable clinical milestones in cancer treatment. A landmark case published in Nature's Oncogene reported a durable complete remission in a patient with treatment-refractory metastatic testicular cancer following a single infusion of AGENT-797 (allo-INKTs) in combination with checkpoint blockade. The patient remains disease-free more than two years post-treatment [1]. Additionally, the company's Phase 2 trial of AGENT-797 in second-line gastric cancer is anticipated to provide additional clinical readouts in 2025 [1].

The company has secured new external funding to advance its clinical programs. A Department of Defense STTR grant was awarded to advance the development of iNKTs for graft-versus-host disease (GvHD) prevention and treatment [1]. Furthermore, a new clinical grant was awarded to initiate a first-in-human clinical trial of iNKTs in GvHD, with trial initiation targeted in the second half of 2025 [1]. These strategic partnerships and clinical milestones have drawn renewed interest from investors and potential partners.

MiNK Therapeutics' financial results for the first half of 2025 reflect ongoing activity supporting its AGENT-797 programs and non-cash expenses, including the impact of repricing certain equity awards. The company ended Q2 2025 with approximately $1.6 million in cash and cash equivalents, which was subsequently raised to $14.6 million through equity sales [1].

MiNK Therapeutics will host a conference call and webcast on August 14, 2025, at 8:30 a.m. ET. Investors can access the live call by dialing (800) 715-9871 (U.S.) or (646) 307-1963 (International) and referencing conference ID 1149380. A live webcast and replay will be available in the Events & Presentations section of MiNK's investor website [1].

References:
[1] https://www.globenewswire.com/news-release/2025/08/14/3133354/0/en/MiNK-Therapeutics-Reports-Clinical-and-Strategic-Milestones-and-Second-Quarter-2025-Results.html